MedTrace Logo

The Use of the Dexcom G6® in Commercial Pilots With Insulin-treated Diabetes

NCT04225455 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2025-11-24

No results posted yet for this study

Summary

To compare glucose control achieved by using real time continuous glucose monitoring (CGMS) Dexcom G6® in combination with self-monitored blood glucose during flight and also with free living in pilots.

Conditions

  • Insulin Dependent Diabetes

Interventions

DEVICE

Glucose monitoring

To compare the glucose monitoring CGMS Dexcom G6® with their usual self-glucose monitoring in pilots by way of assessing times achieved in safe Green flying range, in Amber flying range and in Red flying range as defined by the ARA.MED.330 diabetes protocol. \[Green: 5-15 mmol/L; Amber: 4 to \<5mmol/L and \>15 to 20mmol/L; Red: \<4mmol/L and \>20mmol/L\]

Sponsors & Collaborators

  • DexCom, Inc.

    collaborator INDUSTRY

  • University of Surrey

    lead OTHER

Principal Investigators

  • David Russell-Jones, MD PhD · University of Surrey

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-05
Primary Completion
2025-10-01
Completion
2025-12-30
FDA Device
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04225455 on ClinicalTrials.gov